BMS1P20

Across TCGA pan-cancer cohorts, BMS1P20 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of BMS1P20’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where BMS1P20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BMS1P20 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

LIHC, KICH, and LUAD are the cancer types where BMS1P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BMS1P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.794	<.001	8	view →
KICH	All	All	−0.535	<.001	5	view →
LUAD	Female	All	+0.518	<.001	5	view →
BLCA	All	All	+0.464	.001	5	view →
LUSC	Male	All	+0.483	<.001	4	view →
COAD	Male	All	+0.343	.013	4	view →
HNSC	All	All	+0.239	.027	4	view →
CHOL	Male	All	+1.800	<.001	2	view →
READ	All	All	+0.476	.025	2	view →
BRCA	Female	All	−0.158	.035	2	view →
KIRC	Male	III,IV	−0.254	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

BMS1P20–LIHC

Open the LIHC breakdown →